Gossamer Bio CEO Faheem Hasnain at BIO22 (J.T. MacMillan Photography)

March 17, 2023 10:18 AM EDT

Gossamer stops enrollment on BTK inhibitor program, goes all in on PAH drug

Lei Lei Wu

News Reporter

Gossamer Bio is stopping enrollment on a Phase Ib/II trial of its BTK inhibitor in CNS lymphoma, it said in its

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Lack of detail in Trump's drug price plan raises more questions than answers

Updated: White House threatens ‘most favored nation’ plan to lower US drug prices, but many questions remain

Pharma investors brush off Trump’s ‘most favored nation’ plan as stocks rise

Roche could rethink $50B US expansion plan if new policies 'harm' operations

Exclusive: Patrick Hsu startup launches, looks beyond CRISPR for gene insertion technology

PBM overhaul and drug price negotiations make the cut in Republicans' tax bill